Tyra Biosciences reports Q1 2026 financial results

Tyra Biosciences filed an 8-K on May 13, 2026 to announce its first quarter 2026 financial results. This is a routine quarterly earnings disclosure required for public companies. The actual financial figures—revenue, expenses, cash position, and other metrics—are contained in the press release attached as Exhibit 99.1, which was not included in the filing body text.

For retail investors, this is a standard procedural filing. The key information to review is the attached press release itself, which will detail the company's financial performance for the three months ended March 31, 2026. Watch for management commentary on clinical trial progress, cash runway, and any updates to development timelines in the full press release, as Tyra is a clinical-stage biopharmaceutical company where pipeline progress often matters more than quarterly financials.